Cinclus Pharma Holding AB Sustainability Reports
Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company that develops small molecules for the treatment of gastric acid-related diseases. Its lead product candidate is linaprazan glurate, a potassium-competitive acid blocker designed to treat gastroesophageal reflux disease.
Sector: Professional & technical services
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300TJBPSNZ3DO6B42
FIGI: BBG00S5D7H45
5 reports from 2022 to 2025
